Acorda Therapeutics Inc., of Hawthorne, N.Y., added Harold Safferstein as vice president of business development, appointed Elliot Gruskin vice president of research and development, and promoted Andrew Blight to executive vice president, research and development.

Advanced Viral Research Corp., of Yonkers, N.Y., appointed Raymond Tudor vice president for drug development.

Antex Biologics Inc., of Gaithersburg, Md., appointed Jeffrey Pirone executive vice president and chief financial officer.

Atairgin Technologies Inc., of Irvine, Calif., appointed Debra Liebert vice president of corporate development.

Biogen Inc., of Cambridge, Mass., appointed Hans-Peter Hasler executive vice president, commercial operations.

Chiron Corp., of Emeryville, Calif., named Craig Wheeler president of Chiron BioPharmaceuticals.

Elite Pharmaceuticals Inc., of Northvale, N.J., appointed Eric Sichel to its board.

Elitra Pharmaceuticals Inc., of San Diego, appointed Martin Rosenberg to its board and scientific advisory board and Philip Youngman vice president of discovery biology.

Enanta Pharmaceuticals Inc., of Cambridge, Mass., appointed Ramesh Ratan senior vice president of finance and administration and chief financial officer.

Eos Biotechnology Inc., of South San Francisco, added Barbara Finck as vice president, clinical development.

EraGen Biosciences Inc., of Alachua, Fla., named Karl Voelkerding to its scientific board.

Fluidigm Corp., of South San Francisco, appointed Douglas Modlin vice president of research and development and chief technology officer.

Ganeden Biotech Inc., of Cleveland, appointed Frank Braun vice president of its military and federal programs group.

Genentech Inc., of South San Francisco, appointed Andrew Chan senior director of immunology in its research department.